Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 2/20 | 0.40 |
| ▸ | PAK4 | O96013 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 6/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18325952 | 0.85 | GABRA5 (0.42) | GABRA5PAK4LRRK2HTR1AHPGD | |
| SCHEMBL16346873 | 0.83 | PAK4 (0.44) | GABRA5PAK4LRRK2HTR1A | |
| SCHEMBL16345168 | 0.83 | PAK4 (0.43) | GABRA5PAK4LRRK2HTR1AHPGD | |
| SCHEMBL29611543 | 0.83 | PAK4 (0.41) | GABRA5PAK4LRRK2HTR1AHPGD | |
| SCHEMBL16345086 | 0.83 | PAK4 (0.41) | GABRA5PAK4LRRK2HTR1AHPGD | |
| SCHEMBL28730051 | 0.81 | LRRK2 (0.42) | GABRA5PAK4LRRK2HTR1AHPGD | |
| SCHEMBL18329053 | 0.79 | PAK4 (0.42) | GABRA5PAK4LRRK2HTR1AHPGD | |
| SCHEMBL29999947 | 0.79 | PAK4 (0.42) | GABRA5PAK4LRRK2HTR1AHPGD | |
| SCHEMBL31622713 | 0.78 | GABRA5 (0.45) | GABRA5PAK4LRRK2HTR1AHPGD | |
| SCHEMBL18530652 | 0.77 | PAK4 (0.38) | GABRA5PAK4LRRK2HTR1AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210403459-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2021-12-30 | — | — | US | disclosed |
| US-11008309-B2 | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | Karyopharm Therapeutics Inc. (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200102292-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2020-04-02 | — | — | US | disclosed |
| US-10399963-B2 | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | Karyopharm Therapeutics Inc. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180319779-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2018-11-08 | — | — | US | disclosed |
| US-9856241-B2 | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | Karyopharm Therapeutics Inc. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160368904-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368904-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | BCL6, MALT1, BTK | GABRA5 55/4885PAK4 2007/4885LRRK2 2752/4885 |
| US-20180319779-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | BCL6, MALT1, BTK | GABRA5 48/4885PAK4 2260/4885LRRK2 2579/4885 |
| US-11008309-B2 | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | BCL6, MALT1, BTK | GABRA5 48/4885PAK4 2260/4885LRRK2 2579/4885 |
| US-10399963-B2 | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | BCL6, MALT1, BTK | GABRA5 48/4885PAK4 2260/4885LRRK2 2579/4885 |
| US-20210403459-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | BCL6, MALT1, BTK | GABRA5 48/4885PAK4 2260/4885LRRK2 2579/4885 |
| US-20200102292-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | BCL6, MALT1, BTK | GABRA5 48/4885PAK4 2260/4885LRRK2 2579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.